Pelthos Therapeutics Inc's Business Segments

Pelthos Therapeutics Inc. is a biopharmaceutical company formed on July 1, 2025, through the merger of Channel Therapeutics Corporation and LNHC, Inc. The company’s commercial portfolio includes three FDA-approved products: ZELSUVMI™, XEPI®, and XEGLYZE®. ZELSUVMI™, launched shortly after the merger, is a topical nitric oxide-releasing gel indicated for the treatment of molluscum contagiosum in patients aged one year and older. It is the first FDA-approved topical nitric oxide agent for this condition and is designed for application outside medical settings. Pelthos acquired manufacturing capabilities for the active pharmaceutical ingredient used in ZELSUVMI and the NITRICIL™ technology platform, which enables localized nitric oxide delivery. The company also holds clinical-stage assets targeting the sodium ion channel NaV1.7, a validated pain receptor. In late 2025, Pelthos expanded its product portfolio by acquiring two additional FDA-approved products. In January 2026, the company entered into a $50 million senior secured term loan facility to support commercialization, product launches, working capital, and general corporate purposes. Pelthos licenses the NITRICIL technology platform from Ligand Pharmaceuticals, Inc., which was originally developed by Novan, Inc., focusing on innovative dermatology therapeutics.

The Company operates through two reporting segments: Commercial Operations, which includes the sale, promotion, and commercialization of approved commercial products; and Research and Development, which focuses on developing a novel class of NaV blockers targeting the peripheral nervous system, as well as activities to expand the NITRICIL nitric oxide-based technology. Segment information is disclosed based on the Company's internal organization for operating decisions and financial performance evaluation.